What changed in ten years and what is newly possible or cheap — internal hemorrhoids office based treatment

1. Summary

Ten years of registry and literature activity in this domain sorts into two tracks that barely touch. The office-based, no-sedation track — the one this domain's population is scoped to — has changed by broadening an existing RF predicate rather than by a new dedicated clearance, and by a slow accumulation of disposable delivery instruments around the anoscope class. The second track, carrying almost all of the decade's published clinical-trial and literature volume, is a set of alternatives to surgical hemorrhoidectomy — laser hemorrhoidoplasty, Doppler-guided hemorrhoidal artery ligation, and an emerging transarterial embolization approach — whose own trial eligibility criteria require fitness for sedation or general anesthesia. No office-based, no-sedation US predicate for any of these three was located this pass.

2. What Changed

_Baseline (v1). No prior version; this establishes the starting point for future diffs._

3. Details

RF/electrosurgical delivery — broadened, not deepened

The bipolar/RF electrosurgical product code that already covers this domain's cleared hemorrhoid devices (GEI, 21 CFR 878.4400) is large and heavily used in general: 541 510(k) clearances under that code in the ten years to 2026-09-01, of which this pass scanned the 50 most recent [6]. None of the 50 most recent clearances names a hemorrhoid indication, with one exception that answers a question the domain dossier had left open. K252704, cleared 2025-11-24 to F Care Systems USA, LLC, adds two new electrode accessories to the company's existing "F Care RF System" generator — named in the filing itself as the "Rafaelo probe" and the "Sphera probe" [5]. This is the first US 510(k) record located under that literal accessory name, and it partially resolves the dossier's own open question about whether the internationally marketed "Rafaelo"/"CRA probe" hemorrhoid device is cleared in the US under a different name — it now is, by name, as an accessory. What it does not resolve: the filing's own Indications for Use statement, read verbatim from the summary, never names hemorrhoids or the anal canal — "F Care RF System is intended to conduct radio frequency (RF) current for coagulation from the RF electrosurgical generator to target soft tissue in a broad range of surgical procedures" [5]. The submission's own substantial-equivalence narrative states the only change from the prior predicate (Med RF 4000, K210077) is the addition of these two probes, supported by ex-vivo tissue and biocompatibility testing rather than any hemorrhoid-specific clinical data [5]. So the Rafaelo probe now has a US 510(k) record, but under a generic soft-tissue-coagulation indication — a different regulatory shape than the domain's other RF device family (HET Bipolar Electrocautery), whose own cleared indication names hemorrhoid grades directly.

Disposable delivery vehicles — five clearances in a decade, not three

The disposable single-use anoscope/proctoscope product code (FER, 21 CFR 876.1500) carries five 510(k) clearances in the ten years to 2026-09-01: K171701 (GelPOINT Path Transanal Access Platform, Applied Medical Resources, 2017-07-20) [10], K200021 (Applied Medical Anoscope, 2021-01-06) [9], K230439 (WellCare Anoscope, Well Care (Wuhan) Medical Technology, 2023-12-22) [8], K242668 (Gastro Concepts Air Assist, 2024-12-13) [11], and K250645 (SleeveLUX 24/16 Anoscope/Proctoscope, Haemoband Surgical, 2025-10-09) [7]. Four of the five carry retrievable Indications for Use text this pass. Two read as a plain office instrument: K200021's is "intended for transanal use to provide physicians access to the anal sphincter, anus, and rectum and to perform various diagnostic and therapeutic procedures using additional accessories" [9], and K230439's is worded almost identically [8]. K171701's is meaningfully broader — "multiple instrument or camera access through the anus to perform various diagnostic and/or therapeutic procedures" [10] — closer to a surgical access platform than a simple office anoscope. K250645's is the only one that names hemorrhoids by grade directly: "a class 2 self-illuminating disposable instrument used to assist clinicians when treating and/or diagnose conditions in the anal canal and the lower rectum such as 1st 2nd and 3rd degree hemorrhoids" [7]. K242668's summary PDF could not be retrieved this pass (see §5). Read together, the delivery side of the office anorectal procedure — independent of which energy modality is used through it — is a widening, multi-entrant field, which is the shape of "newly cheap" this pass located: no premarket barrier problem, more suppliers, no single dominant instrument.

Adjacent modalities — where the published and trial-registry volume actually is

A 2026 bibliometric analysis of 2,764 hemorrhoid-therapy publications indexed in Web of Science over the past two decades found that "burst detection and thematic evolution mapping highlighted emerging frontiers such as minimally invasive techniques (Doppler-guided hemorrhoidal artery ligation (DG-HAL), laser hemorrhoidoplasty), day surgery/ambulatory management, evidence-based guidelines, and long-term outcomes/comparative effectiveness" [1]. None of the three named frontiers is an office, no-sedation modality as this domain scopes its population: two currently recruiting trials comparing energy-based approaches to conventional hemorrhoidectomy both name anesthesia or sedation fitness as an eligibility criterion — one requires patients "fit for general anesthesia or sedation" [15] [sponsor-reported], the other is titled around radiofrequency ablation versus DG-HAL for disease "requiring surgical management" [14] [sponsor-reported].

A five-year, single-center, double-blind RCT (n=121 randomized, 102 followed to five years, 34 per arm, grade II-III hemorrhoids) found Kaplan-Meier five-year symptom recurrence of 24% (excisional hemorrhoidectomy), 29% (laser hemorrhoidoplasty) and 44% (sutured mucopexy), a difference the authors report did not reach statistical significance (log-rank p=0.076), while general health evaluation scores were highest in the laser hemorrhoidoplasty arm [2] [single-source]. A systematic review and meta-analysis of five comparative studies on Doppler- guided versus non-Doppler-guided hemorrhoidal-artery-ligation-with-rectoanal-repair found no significant difference in operative time or postoperative bleeding between the two, more postoperative urinary retention with the Doppler-guided version, and lower recurrence with the non-Doppler version (odds ratio 5.12 favoring non-DG, p<0.001) — the review's own conclusion states this "would provide some cost savings for institutions who are unable to procure the necessary equipment for DG HAL-RAR" [3] [single-source].

A newer modality with no cleared-device or office-setting precedent located this pass is transarterial hemorrhoidal (superior rectal) artery embolization, an interventional-radiology technique. A systematic review of 15 studies (mean patient age ranging 40.5-72.2 years across studies, 424 embolized arteries total) found "no major complication or death…in 12 studies" and re-embolization or after-treatment surgery in 11.79% (27/229) of patients for surgical failure or symptom recurrence [4] [single-source]. Two currently recruiting studies extend this line: a UCLA-sponsored single-arm trial (estimated enrollment 22) measuring bleeding-symptom reduction at 12 months post-procedure [13] [sponsor-reported], and a Swedish single-arm device study of "PexyEazy®," a suture-based mucopexy device (estimated enrollment 35, sponsor Developeration AB) whose primary outcomes are measured "directly after the surgical procedure" [12] [sponsor-reported] — both procedural designs, not office-based-without-sedation ones.

4. Sources

[1] Global knowledge mapping and technological evolution in hemorrhoid therapy: a multi-tool bibliometric analysis — Updates in Surgery (published 2026-08, day not given in the PubMed record; accessed 2026-09-01). PMID 41266707 — https://pubmed.ncbi.nlm.nih.gov/41266707/ [peer-reviewed] [2] Five-Year Follow-up of the Double-Blind Randomized Controlled Trial Comparing Laser Hemorrhoidoplasty With Sutured Mucopexy and Excisional Hemorrhoidectomy — Diseases of the Colon & Rectum (published 2026-07-21; accessed 2026-09-01). PMID 42478482 — https://pubmed.ncbi.nlm.nih.gov/42478482/ [peer-reviewed] [3] Haemorrhoid artery ligation - recto anal repair (HAL-RAR) blind versus Doppler: a systematic review and meta-analysis — ANZ Journal of Surgery (published 2024-11, day not given in the PubMed record; accessed 2026-09-01). PMID 39465535 — https://pubmed.ncbi.nlm.nih.gov/39465535/ [peer-reviewed] [4] Arterial Embolization for the Internal Hemorrhoids Management: A Systematic Review — Health Science Reports (published 2026-01, day not given in the PubMed record; accessed 2026-09-01). PMID 41503542 — https://pubmed.ncbi.nlm.nih.gov/41503542/ [peer-reviewed] [5] FDA 510(k) Summary — F Care RF System (F Care Systems USA, LLC) — U.S. Food and Drug Administration (decided 2025-11-24; accessed 2026-09-01). K252704 — https://www.accessdata.fda.gov/cdrh_docs/pdf25/K252704.pdf [federal-registry] [6] openFDA Device 510(k) and Classification Databases, product code GEI (Electrosurgical, Cutting & Coagulation & Accessories) — U.S. Food and Drug Administration (a live database, no single publication date; accessed 2026-09-01). 21 CFR 878.4400 — https://api.fda.gov/device/510k.json?search=product_code:GEI+AND+decision_date:%5B2016-09-03+TO+2026-09-01%5D [federal-registry] [7] FDA 510(k) Summary — SleeveLUX 24/16 Anoscope/Proctoscope (Haemoband Surgical, Ltd.) — U.S. Food and Drug Administration (decided 2025-10-09; accessed 2026-09-01). K250645 — https://www.accessdata.fda.gov/cdrh_docs/pdf25/K250645.pdf [federal-registry] [8] FDA 510(k) Summary — WellCare Anoscope (Well Care (Wuhan) Medical Technology Co., Ltd.) — U.S. Food and Drug Administration (decided 2023-12-22; accessed 2026-09-01). K230439 — https://www.accessdata.fda.gov/cdrh_docs/pdf23/K230439.pdf [federal-registry] [9] FDA 510(k) Summary — Applied Medical Anoscope (Applied Medical Resources Corp.) — U.S. Food and Drug Administration (decided 2021-01-06; accessed 2026-09-01). K200021 — https://www.accessdata.fda.gov/cdrh_docs/pdf20/K200021.pdf [federal-registry] [10] FDA 510(k) Summary — GelPOINT Path Transanal Access Platform (Applied Medical Resources Corp.) — U.S. Food and Drug Administration (decided 2017-07-20; accessed 2026-09-01). K171701 — https://www.accessdata.fda.gov/cdrh_docs/pdf17/K171701.pdf [federal-registry] [11] FDA 510(k) Clearance Record — Gastro Concepts Air Assist (Gastro Concepts, LLC) — U.S. Food and Drug Administration (decided 2024-12-13; accessed 2026-09-01; summary PDF not retrievable this pass, see §5). K242668 — https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K242668 [federal-registry] [12] SCI-Pex Study — Safety and Performance of PexyEazy®, a Device for Treatment of Hemorrhoids — ClinicalTrials.gov (protocol last updated 2025-03-07; accessed 2026-09-01; status recruiting, no results posted). NCT05782010 — https://clinicaltrials.gov/study/NCT05782010 [trial-registry] [13] Hemorrhoidal Artery Embolization: Longitudinal Impact On Symptoms (HELIOS) — ClinicalTrials.gov (protocol last updated 2026-02-02; accessed 2026-09-01; status recruiting, no results posted). NCT07179601 — https://clinicaltrials.gov/study/NCT07179601 [trial-registry] [14] Radiofrequency Ablation vs Doppler-guided Haemorrhoidal Artery Ligation in the Treatment of Haemorrhoidal Disease — ClinicalTrials.gov (protocol last updated 2026-03-13; accessed 2026-09-01; status recruiting, no results posted). NCT06170736 — https://clinicaltrials.gov/study/NCT06170736 [trial-registry] [15] HELO Trial: Energy-Based Therapies vs. Conventional Hemorrhoidectomy for Grade III Hemorrhoids — ClinicalTrials.gov (protocol last updated 2026-08-07; accessed 2026-09-01; status recruiting, no results posted). NCT07333040 — https://clinicaltrials.gov/study/NCT07333040 [trial-registry]

5. Sourcing & Gaps

Well established: that the modalities carrying most of the decade's published and registered-trial growth (laser hemorrhoidoplasty, DG-HAL, transarterial embolization) sit outside an office/no-sedation population rests on ≥2 independent sources agreeing — a bibliometric analysis naming them as the field's emerging frontiers [1] and two separate trial sponsors' own eligibility criteria requiring anesthesia or sedation fitness [14][15] — and is stated plainly in §3 rather than marked, on that basis. That the disposable-anoscope product code has grown to five clearances in ten years is a plain registry count [7][8][9][10][11], not a directional claim, and carries no marker for the same reason no marker is put on any single K-number's existence elsewhere in this domain's dossier.

Thin: the Rafaelo-probe finding rests on one 510(k) filing [5] — a second, independent source (a company announcement, a CE-marking record, or a second regulatory filing) was not sought this pass. The five-year RCT [2], the DG-HAL systematic review [3], and the embolization systematic review [4] are each a single retrieved document; no second source was checked against any of their specific numeric findings.

Rescoped from class 3: none in this report — every proposition here is a registry fact or a published measured finding, not a question about what a person would do.

Out of scope: MAUDE complaint/failure-mode data for any device named here — no connector in this repo reaches it. Device or consumable pricing for any RF console, probe, or anoscope named here. Non-US regulatory status of the Rafaelo probe or any laser-hemorrhoidoplasty device (CE marking, EU trial registrations) — this domain's scope is US jurisdiction only. Whether the disposable-anoscope class's growth reflects falling per-unit manufacturing cost or a different driver (reimbursement, litigation exposure of reusable instruments) was not researched — that is this report's own inference boundary, not a finding.

Not searched vs. not found: K242668's Indications for Use text was sought and not found this pass — the summary PDF returned HTTP 401 at the year-2024 path and HTTP 404 at the bare path, which FDA's own repository documentation records as either an incomplete posting or a 510(k) statement filed in place of a summary, not evidence about the device's indication [11]. Impedance-based dosimetry or automatic-cutoff feature precedent in any cleared electrosurgical device — a gap the domain dossier's §7 had already named — was not searched this pass either; no query was run for it. A CE-marking or EU-registry search for the Rafaelo/CRA-probe device by name was not searched, consistent with the domain's US-only scope rather than a finding that no such record exists.

[inference] The two-track split this pass found — a broadened predicate serving the in-scope office/no-sedation niche, against rapid published and trial-registry growth in sedation-requiring modalities — suggests that any future in-office device claiming durability at grade III will be measured, in the literature a Verifier or Corroborator would eventually be pointed at, against surgical-modality benchmarks the field is actively generating (laser hemorrhoidoplasty, DG-HAL, embolization), not only against the RBL/IRC comparators the domain dossier's §5 already documents. This is this report's own synthesis, not a sourced finding.

6. Claim Candidates